Neuromyelitis Optica Spectrum Disorder Relapse Clinical Trial
Official title:
Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders
Neuromyelitis Optica Spectrum Disorders (NMOSD) is associated with a pathological humoral immune response against the aquaporin-4(AQP-4) water channel. Rucotinib is an oral inhibitor of JAK1 and JAK2 tyrosine kinases. It may benefit some patients with NMOSD due to the important role of JAK/STAT signaling pathway in the pathogenesis of NMOSD. Clincial trials may be needed to observe its efficacy and safety.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04131764 -
Diagnosis of ON With or Without MS or NMOSD
|